Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance

Clinical Laboratory

Volumn 49, Issue 11-12, 2003, Pages 571-576

  Pfützner, Andreas ^a,b   Langenfeld, Matthias ^a   Kunt, Thomas ^c   Löbig, Mirjam ^a   Forst, Thomas ^a  

^a IKFE GmbH   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c Al Zayed Hospital   (United Arab Emirates)

Author keywords

Assay evaluation; Insulin resistance; Intact proinsulin; Resistin

Indexed keywords

EPITOPE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PROINSULIN; RESISTIN; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; BODY MASS; CALCULATION; CALIBRATION; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE DURATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; INSULIN RESISTANCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PH; PREVALENCE; PROTEIN BLOOD LEVEL; QUALITY CONTROL; SCORING SYSTEM; SEX RATIO; STANDARDIZATION; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD DEPRIVATION; HORMONES, ECTOPIC; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROINSULIN; REPRODUCIBILITY OF RESULTS; RESISTIN;

PHOENIX;

EID: 17544404866     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104:517-529
2. Kahn BB and Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473-481
3. DeFronzo RA, Bonadonna RE, Ferranini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15:318-368
4. Steppan CM, Lazar MA. Resistin and obesity-asociated insulin resistance. Trends Endocrinol Metab 2002; 13:18-23
5. Steppan MC, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312
6. Way JM, Gorgum CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR, Willson TM, Kliewer SA, Hotamisligil GS. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276:25651-25653
7. Juan CC, Au LC, Fang VS, Kang SF, Ko YH, Kuo SF et al. Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 2001; 289:1328-1333
8. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285:561-564
9. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50:2199-2202
10. Wang H, Chu WS, Hemphill C, Elbein SC. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 2002; 87:2520-2524
11. Engert JC, Vohl MC, Williams SM, Lepade P, Loredo-Osti JC, Faith J et al. 5′ flanking variants of resistin are associated with obesity. Diabetes 2002; 51:1629-1634
12. Sentinelli F, Romeo S, Arca M, Filippi E, Legnetti F, Banchieri M et al. Human resistin gene, obesity, and type 2 diabetes: mutation analysis and population study. Diabetes 2002; 51:860-862
13. Osawa H, Onuma H, Murakami A, Ochi M, Nishimiya T, Kato K, et al. Systematic search for single nucleotide polymorphisms in the resistin gene: the absence of evidence for the association of three identified single nucleotide polymorphisms with Japanese type 2 diabetes. Diabetes 2002; 51:863-866
14. Ukkola O. Resistin - a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002; 147:571-574
15. Luzio SD, Lucas I, Owens DR. Importance of validation of immunoassays for intact proinsulin. Clin Chem Lab Med 2001; 39:631-3.
16. Pfützner A, Kunt T, Langenfeld M, Löbig M, Knesovic M, Forst T. Clinical and laboratory evaluation characteristics of specific chemiluminescence assays for intact and total proinsulin. Clin Chem Lab Med 2003;41:1234-1238
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419
18. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetic Med 2000; 17:299-30
19. Passing H, Bablok W. Comparison of several regression procedures for method comparison studies and determination of sample sizes. Application of linear regression procedures for method comparison studies in clinical chemistry, Part II. J Clin Chem Clin Biochem 1984, 22:431-445
20. Pfützner A, Standl E, Schulze J, Pahler S, Larbig M, Lübben G, Forst T: Results from the IRIS-II study: High fasting output of uncleaved intact proinsulin from the pancreatic β-cell is a specific marker for insulin resistance. Diabetes 2003; 52 (Suppl. 1): A542
21. Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22:36-52
22. Steinberg HO, Baron AD: H. Steinberg et al.: Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45:623-634
23. Haffner SM, D'Agostino R, Jr., Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22:562-568
24. Laakso M: Insulin resistance and its impact on the approach to therapy of type 2 diabetes. Int J Clin Pract 2001; Suppl 8-12
25. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyorala K, Salonen JT, Karhapaa P: Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991; 11:1068-1076
26. Bressler P, Bailey SR, Matsuda M, DeFronzo RA: Insulin resistance and coronary artery disease. Diabetologia 1996; 39:1345-1350
27. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R: Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93:1809-1817
28. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R, Muggeo M: HOMA-Estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25:1135-1141
29. Wallace TM, Matthews DR: The assessment of insulin resistance in man. Diabet Med 2002; 19:527-534
30. Forst T, Hohberg C, Mondok A, Pahler S, Konrad T, Lübben G, Pfützner A: Intact Proinsulin is a highly specific indicator of Insulin Resistance in Type 2 Diabetes. Diabetes 2003; 52 (Suppl. 1):A459